An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Top results in this bookTable of Contents
GeneReviews® [Internet].
Adam MP, Bick S, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2026.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Non-Alcoholic Fatty Liver Disease: Assessment and Management.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 49.)
Metreleptin (Myalepta): Therapeutic area: Leptin deficiency in lipodystrophy: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct.
Endotext [Internet].
Feingold KR, Adler RA, Ahmed SF, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): CADTH Reimbursement Review: Therapeutic area: Cystic fibrosis, F508del-CFTR mutation, 6 years and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Etranacogene Dezaparvovec (Hemgenix): Therapeutic area: Hemophilia B: CADTH Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Sep.
Fidanacogene Elaparvovec (Beqvez): CADTH Reimbursement Review: Therapeutic area: Hemophilia B [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
Cystic Fibrosis: Diagnosis and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)
Lomitapide (Juxtapid) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.
Clinical Review Report: Lumacaftor/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication: For the treatment of cystic fibrosis in patients aged six years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-Term Safety Period, Double-Blind, Placebo-Controlled Discontinuation Phase, and Open Label Restabilization Period (COLT2) [Internet].
Findling R, Taylor-Zapata P, Anand R, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Bethesda (MD): National Institute of Child Health and Human Development (US); 2015 Dec 1.
NTP Technical Report on the Toxicity Studies of Perfluoroalkyl Carboxylates (Perfluorohexanoic Acid, Perfluorooctanoic Acid, Perfluorononanoic Acid, and Perfluorodecanoic Acid) Administered by Gavage to Sprague Dawley (Hsd:Sprague Dawley SD) Rats (Revised): Toxicity Report 97 [Internet].
National Toxicology Program.
Research Triangle Park (NC): National Toxicology Program; 2022 Jul.
Sotorasib (Lumakras): Therapeutic area: KRAS G12C-mutated, advanced non–small cell lung cancer: CADTH Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jul.
Toxicological Profile for Dinitrotoluenes.
Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); 2016 Feb.
Toxicological Profile for Chloroform.
Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); 2024 Oct.
Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Therapeutic area: Cystic fibrosis, F508del or responsive CFTR mutation, in patients aged 6 years and older: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2026 Mar.
Odevixibat (Bylvay): CADTH Reimbursement Review: Therapeutic area: Progressive familial intrahepatic cholestasis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
Frequency of Meals and/or Snacking and Growth, Body Composition, and Risk of Obesity: A Systematic Review [Internet].
Palacios C, Raynor HA, Anderson CAM, et al.
Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2024 Nov.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on